검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Arlocabtagene Autoleucel (Arlocabtagene Autoleucel) Juno Therapeutics, Inc., a Bristol…·Multiple Myeloma 3 trials |
|---|---|
Overview Program | Arlocabtagene Autoleucel |
Overview Company | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
Overview Modality | CGT |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting G protein-coupled receptor |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | Cytokine release syndrome (CRS) occurred in 82% of patients, immune effector cell-associated neurotoxicity syndrome in 10%, and other select neurotoxicities in 12%; most were grade 1/2 and frequency appeared dose-dependent. |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.. Patients with relapsed/refractory multiple myeloma (RRMM) have limited treatment options. Arlocabtagene autoleucel (arlo-cel, BMS-986393) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). Thi… |
Toxicology CRS | 82% |
Clinical Data Tier / Score | A · 12 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Arlocabtagene Autoleucel (Arlocabtagene Autoleucel) Juno Therapeutics, Inc., a Bristol…·Multiple Myeloma 3 trials |
|---|---|
Overview Program | Arlocabtagene Autoleucel |
Overview Company | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
Overview Modality | CGT |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting G protein-coupled receptor |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | Cytokine release syndrome (CRS) occurred in 82% of patients, immune effector cell-associated neurotoxicity syndrome in 10%, and other select neurotoxicities in 12%; most were grade 1/2 and frequency appeared dose-dependent. |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.. Patients with relapsed/refractory multiple myeloma (RRMM) have limited treatment options. Arlocabtagene autoleucel (arlo-cel, BMS-986393) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). Thi… |
Toxicology CRS | 82% |
Clinical Data Tier / Score | A · 12 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교